Compare HIMS & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HIMS | LGND |
|---|---|---|
| Founded | 2017 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 6.2B |
| IPO Year | 2019 | 1997 |
| Metric | HIMS | LGND |
|---|---|---|
| Price | $18.55 | $301.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 11 |
| Target Price | $28.31 | ★ $361.27 |
| AVG Volume (30 Days) | ★ 12.7M | 177.1K |
| Earning Date | 11-09-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2886.36 |
| EPS | N/A | ★ 0.31 |
| Revenue | ★ $2,347,637,000.00 | $141,102,000.00 |
| Revenue This Year | $33.80 | $8.82 |
| Revenue Next Year | $23.08 | $31.67 |
| P/E Ratio | ★ N/A | $1,000.90 |
| Revenue Growth | ★ 59.00 | 29.48 |
| 52 Week Low | $13.74 | $175.89 |
| 52 Week High | $40.99 | $326.63 |
| Indicator | HIMS | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 31.83 | 46.43 |
| Support Level | $13.74 | $280.42 |
| Resistance Level | $30.72 | $319.83 |
| Average True Range (ATR) | 2.12 | 12.09 |
| MACD | -0.78 | -1.04 |
| Stochastic Oscillator | 1.66 | 18.81 |
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.